Obat.Jk

OBAT.JK maintains a strong liquidity position, with a current ratio of 6.65, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score further supports this, showing a low liquidity risk. However, the company reported a negative free cash flow of -5,330,647,960 IDR, which may signal potential challenges in sustaining operations without external financing.

In terms of profitability, OBAT.JK demonstrates a return on equity (ROE) of 21.18% and a return on assets (ROA) of 17.28%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is performing well relative to industry standards, although specific comparisons to cohort medians are not available in the provided data.

The company's revenue is concentrated within the pharmaceuticals segment, with no disclosed geographic diversification. This concentration may pose a risk if market conditions in the primary operating region deteriorate. The company's growth trajectory is supported by a positive operating cash flow of 23,723,588,610 IDR, indicating the ability to fund operations and potentially invest in future growth.

Risk factors for OBAT.JK include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The company's capital structure is also favorable, with a debt-to-equity ratio of 0.07, suggesting a conservative approach to leverage.

Recent events, such as filings and transcripts, have not indicated any significant changes in the company's financial or operational status. The company's capital expenditure of -20,569,340,730 IDR suggests a focus on cost management rather than expansion.